Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer

H. Skálová, N. Hájková, B. Majerová, M. Bártů, C. Povýšil, I. Tichá,

. 2019 ; 18 (4) : 3014-3024. [pub] 20190820

Language English Country Greece

Document type Journal Article

The importance of the expression profile of claudins in the molecular classification of breast cancer (BC) is currently under investigation. Claudins, together with cadherins, serve an important role in the epithelial-mesenchymal transition and influence the chemosensitivity of cancer cells. Adjuvant chemotherapy is administered following surgical resection in selected cases of BC. Previous neoadjuvant chemotherapy may change the molecular profile of a tumour and subsequently also its chemosensitivity. In the current study, the expression of claudin-1, -3 and -4, E- and N-cadherin and the standard BC biomarkers [oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and marker of proliferation Ki-67 (Ki-67)] in formalin-fixed, paraffin-embedded sections from 62 patients with invasive BC was analysed using immunohistochemistry prior to and following neoadjuvant chemotherapy. The results revealed increased expression of claudin-1 (P=0.03) and decreased expression of claudin-3 (P=0.005), PR (P<0.001) and Ki-67 (P=0.01) following the neoadjuvant therapy. No significant changes in the expression of ER, claudin-4 or E- and N-cadherin were observed following therapy. Furthermore, an association between the expression of claudin-1 and the standard BC markers (P<0.05) was identified. A high expression of claudin-1 was more frequently observed in the triple-negative BC cohort than in the cohort with positive ER, PR and/or HER2 before (P=0.04) and after chemotherapy (P=0.02). The expression of N-cadherin was associated with the expression of ER, PR, HER2 and tumour grade (P<0.05). A positive association between the expression of claudin-3 and E-cadherin (P=0.005) was observed. No association was found between the expression of E- and N-cadherin. In conclusion, significant changes in the expression of claudin-1 and -3 but not in the expression of claudin-4, E- and N-cadherin were observed in samples taken from patients with BC following chemotherapy. These findings indicate that claudins-1 and -3 serve a role in the response of BC to chemotherapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044262
003      
CZ-PrNML
005      
20200109095635.0
007      
ta
008      
200107s2019 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/etm.2019.7930 $2 doi
035    __
$a (PubMed)31572543
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Skálová, Helena $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic.
245    10
$a Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer / $c H. Skálová, N. Hájková, B. Majerová, M. Bártů, C. Povýšil, I. Tichá,
520    9_
$a The importance of the expression profile of claudins in the molecular classification of breast cancer (BC) is currently under investigation. Claudins, together with cadherins, serve an important role in the epithelial-mesenchymal transition and influence the chemosensitivity of cancer cells. Adjuvant chemotherapy is administered following surgical resection in selected cases of BC. Previous neoadjuvant chemotherapy may change the molecular profile of a tumour and subsequently also its chemosensitivity. In the current study, the expression of claudin-1, -3 and -4, E- and N-cadherin and the standard BC biomarkers [oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and marker of proliferation Ki-67 (Ki-67)] in formalin-fixed, paraffin-embedded sections from 62 patients with invasive BC was analysed using immunohistochemistry prior to and following neoadjuvant chemotherapy. The results revealed increased expression of claudin-1 (P=0.03) and decreased expression of claudin-3 (P=0.005), PR (P<0.001) and Ki-67 (P=0.01) following the neoadjuvant therapy. No significant changes in the expression of ER, claudin-4 or E- and N-cadherin were observed following therapy. Furthermore, an association between the expression of claudin-1 and the standard BC markers (P<0.05) was identified. A high expression of claudin-1 was more frequently observed in the triple-negative BC cohort than in the cohort with positive ER, PR and/or HER2 before (P=0.04) and after chemotherapy (P=0.02). The expression of N-cadherin was associated with the expression of ER, PR, HER2 and tumour grade (P<0.05). A positive association between the expression of claudin-3 and E-cadherin (P=0.005) was observed. No association was found between the expression of E- and N-cadherin. In conclusion, significant changes in the expression of claudin-1 and -3 but not in the expression of claudin-4, E- and N-cadherin were observed in samples taken from patients with BC following chemotherapy. These findings indicate that claudins-1 and -3 serve a role in the response of BC to chemotherapy.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hájková, Nikola $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic.
700    1_
$a Majerová, Barbora $u First Faculty of Medicine, Charles University, 12108 Prague, Czech Republic.
700    1_
$a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic.
700    1_
$a Povýšil, Ctibor $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic.
700    1_
$a Tichá, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic.
773    0_
$w MED00191503 $t Experimental and therapeutic medicine $x 1792-0981 $g Roč. 18, č. 4 (2019), s. 3014-3024
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31572543 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200107 $b ABA008
991    __
$a 20200109100004 $b ABA008
999    __
$a ind $b bmc $g 1480851 $s 1082932
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 18 $c 4 $d 3014-3024 $e 20190820 $i 1792-0981 $m Experimental and therapeutic medicine $n Exp Ther Med $x MED00191503
LZP    __
$a Pubmed-20200107

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...